Bertelsmann Investments acquires stake in Author-it Software Corporation

Bertelsmann Investments makes mid-single-digit million investment in Author-it Software Corporation, which improves efficiency in creating regulated documents for pharmaceutical companies.

Guetersloh / New Zealand - Bertelsmann Investments (BI) recently made a mid-single-digit million strategic investment in Author-it Software Corporation (ASC), a New Zealand-based company that develops component-based regulated document creation solutions for pharmaceutical companies. ASC is the developer of Docuvera, a platform that aims to drive efficiencies in the life sciences industry by helping B2B customers efficiently author, review, approve, translate and publish regulated documents.

We see great opportunities for the digital health market as a whole and have already invested €90 million in the market since last year.

Carsten Coesfeld, CEO of Bertelsmann Investments

This investment comes as part of Bertelsmann Investments' commitment to digital health. The company has already invested a total of €90 million in the digital health market since 2021.

The investment in Docuvera is a great opportunity to be part of the transformative development in the pharma sector.

Tobias Beer, Managing Director of RED LIST.

Bertelsmann Investments' investment is supported by a strategic collaboration with Rote Liste Service GmbH (ROTE LISTE), an established company in the German healthcare sector. Together, they plan to optimize pharmaceutical content creation processes to increase efficiency for pharmaceutical companies.

Paul Reid, CEO of Author-it Software Corporation, is pleased with the trust Bertelsmann Investments has placed in his company. He emphasizes that their products are aimed at helping pharmaceutical companies create and reuse information efficiently. Overall, this investment by Bertelsmann Investments in Docuvera demonstrates their commitment to the digital health market and collaboration with established companies.